Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announces that its placebo-controlled phase 2b Digoxin Immune Fab (DIF) Efficacy Evaluation in P
read more » Discuss Add this link to...Bury Add to:
| Bookmarks